157 related articles for article (PubMed ID: 22077480)
1. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Celia C; Cosco D; Paolino D; Fresta M
Expert Opin Drug Deliv; 2011 Dec; 8(12):1609-29. PubMed ID: 22077480
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.
Federico C; Morittu VM; Britti D; Trapasso E; Cosco D
Int J Nanomedicine; 2012; 7():5423-36. PubMed ID: 23139626
[TBL] [Abstract][Full Text] [Related]
3. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
Paolino D; Licciardi M; Celia C; Giammona G; Fresta M; Cavallaro G
Eur J Pharm Biopharm; 2012 Sep; 82(1):94-102. PubMed ID: 22705641
[TBL] [Abstract][Full Text] [Related]
4. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
5. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Garg NK; Dwivedi P; Campbell C; Tyagi RK
Eur J Pharm Sci; 2012 Dec; 47(5):1006-14. PubMed ID: 23041219
[TBL] [Abstract][Full Text] [Related]
6. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs.
Licciardi M; Paolino D; Celia C; Giammona G; Cavallaro G; Fresta M
Biomaterials; 2010 Oct; 31(28):7340-54. PubMed ID: 20609469
[TBL] [Abstract][Full Text] [Related]
7. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
8. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
10. Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy.
Licciardi M; Paolino D; Mauro N; Cosco D; Giammona G; Fresta M; Cavallaro G; Celia C
ChemMedChem; 2016 Aug; 11(16):1734-44. PubMed ID: 27273893
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches to deliver gemcitabine to cancers.
Reddy LH; Couvreur P
Curr Pharm Des; 2008; 14(11):1124-37. PubMed ID: 18473859
[TBL] [Abstract][Full Text] [Related]
13. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Moog R; Burger AM; Brandl M; Schüler J; Schubert R; Unger C; Fiebig HH; Massing U
Cancer Chemother Pharmacol; 2002 May; 49(5):356-66. PubMed ID: 11976829
[TBL] [Abstract][Full Text] [Related]
14. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
15. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.
Gaudin A; Song E; King AR; Saucier-Sawyer JK; Bindra R; Desmaële D; Couvreur P; Saltzman WM
Biomaterials; 2016 Oct; 105():136-144. PubMed ID: 27521616
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Paolino D; Cosco D; Racanicchi L; Trapasso E; Celia C; Iannone M; Puxeddu E; Costante G; Filetti S; Russo D; Fresta M
J Control Release; 2010 Jun; 144(2):144-50. PubMed ID: 20184929
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
[TBL] [Abstract][Full Text] [Related]
18. Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Dyawanapelly S; Kumar A; Chourasia MK
Crit Rev Ther Drug Carrier Syst; 2017; 34(1):63-96. PubMed ID: 28322141
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa P; Immordino ML; Rocco F; Cattel L
Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
